WO1997046672A3 - Antisense nucleic acids and hammerhead ribozymes - Google Patents

Antisense nucleic acids and hammerhead ribozymes Download PDF

Info

Publication number
WO1997046672A3
WO1997046672A3 PCT/EP1997/002923 EP9702923W WO9746672A3 WO 1997046672 A3 WO1997046672 A3 WO 1997046672A3 EP 9702923 W EP9702923 W EP 9702923W WO 9746672 A3 WO9746672 A3 WO 9746672A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
antisense nucleic
hammerhead ribozymes
antisense
antisense constructs
Prior art date
Application number
PCT/EP1997/002923
Other languages
French (fr)
Other versions
WO1997046672A2 (en
Inventor
Georg Sczakiel
Rainer Haas
Ralf Kronenwett
Original Assignee
Deutsches Krebsforsch
Georg Sczakiel
Rainer Haas
Ralf Kronenwett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Georg Sczakiel, Rainer Haas, Ralf Kronenwett filed Critical Deutsches Krebsforsch
Priority to EP97925049A priority Critical patent/EP0951540A2/en
Priority to JP10500233A priority patent/JP2000511428A/en
Publication of WO1997046672A2 publication Critical patent/WO1997046672A2/en
Publication of WO1997046672A3 publication Critical patent/WO1997046672A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to antisense constructs, particularly antisense nucleic acids and hammerhead ribozymes, which are specific for transcripts encoded by chromosomal translocations, such as the bcr-abl fusion as well as to pharmaceutical compositions containing said antisense constructs.
PCT/EP1997/002923 1996-06-05 1997-06-05 Antisense nucleic acids and hammerhead ribozymes WO1997046672A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97925049A EP0951540A2 (en) 1996-06-05 1997-06-05 Antisense nucleic acids and hammerhead ribozymes
JP10500233A JP2000511428A (en) 1996-06-05 1997-06-05 Antisense nucleic acids and hammerhead ribozymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96109034 1996-06-05
EP96109034.7 1996-06-05

Publications (2)

Publication Number Publication Date
WO1997046672A2 WO1997046672A2 (en) 1997-12-11
WO1997046672A3 true WO1997046672A3 (en) 1998-03-26

Family

ID=8222852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/002923 WO1997046672A2 (en) 1996-06-05 1997-06-05 Antisense nucleic acids and hammerhead ribozymes

Country Status (3)

Country Link
EP (1) EP0951540A2 (en)
JP (1) JP2000511428A (en)
WO (1) WO1997046672A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10202419A1 (en) * 2002-01-22 2003-08-07 Ribopharma Ag Method of inhibiting expression of a target gene resulting from chromosome aberration
GB0216929D0 (en) * 2002-07-20 2002-08-28 Milner Anne J Silencing of gene expression
CN100490903C (en) * 2006-11-13 2009-05-27 重庆医科大学 Oligonucleotide for targeted activation of chronic granulocyte leukaemia protein kinase PKR and application thereof
US20110071214A1 (en) * 2008-05-14 2011-03-24 Gregory John Allen Methods and compositions for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
WO1994013793A1 (en) * 1992-12-04 1994-06-23 Apollon, Inc. Compounds and methods for the treatment of leukemias
WO1996012803A1 (en) * 1994-10-24 1996-05-02 Genset Method for the ex vivo treatment of tumour cells from patients with cml

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
WO1994013793A1 (en) * 1992-12-04 1994-06-23 Apollon, Inc. Compounds and methods for the treatment of leukemias
WO1996012803A1 (en) * 1994-10-24 1996-05-02 Genset Method for the ex vivo treatment of tumour cells from patients with cml

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HOMANN, M. ET AL.: "Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1", NUCLEIC ACIDS RESEARCH., vol. 21, 1993, OXFORD GB, pages 2809 - 2814, XP002051227 *
JAMES H ET AL: "Investigating and improving the specificity of ribozymes directed against the bcr - abl translocation", LEUKEMIA, (1996 JUN) 10 (6) 1054-64., XP002051229 *
KRONENWETT R ET AL: "Kinetic selectivity of complementary nucleic acids: bcr - abl -directed antisense RNA and ribozymes.", JOURNAL OF MOLECULAR BIOLOGY, (1996 JUN 21) 259 (4) 632-44., XP002051230 *
PUBLISHED ERRATUM APPEARS IN LEUKEMIA 1996 OCT;10(10):1676. *
RITTNER, K. ET AL.: "In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1", NUCLEIC ACIDS RESEARCH., vol. 21, 1993, OXFORD GB, pages 1381 - 1387, XP002051228 *
SNYDER D S ET AL: "RIBOZYME-MEDIATED INHIBITION OF BCR-ABL GENE EXPRESSION IN A PHILADELPHIA CHROMOSOME-POSITIVE CELL LINE", BLOOD, vol. 82, no. 2, 15 July 1993 (1993-07-15), pages 600 - 605, XP000576879 *
TABLER, M. ET AL.: "A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design", NUCLEIC ACIDS RESEARCH., vol. 22, 1994, OXFORD GB, pages 3958 - 3965, XP002051226 *

Also Published As

Publication number Publication date
JP2000511428A (en) 2000-09-05
EP0951540A2 (en) 1999-10-27
WO1997046672A2 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
HK1072729A1 (en) Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
ZA200005478B (en) Shampoo compositions.
AU4048299A (en) Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
ZA200300744B (en) Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same.
ZA99355B (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them.
WO2002016340A8 (en) Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
WO2001042441A3 (en) Plastid transformation
EP1430016A4 (en) 3,4,5-trimethoxy phenyl-based ester compound and preparation method thereof and whitening cosmetic composition containing the same
ZA99357B (en) Pentasaccharides, process for their preparation and pharmaceutical compositions containing them.
WO1997046672A3 (en) Antisense nucleic acids and hammerhead ribozymes
WO2003057847A8 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
EP1123695A3 (en) Oral composition comprising capsules containing keratin
HUP0001058A3 (en) 5-hydroxymethyl-2-aminotetralins as cardiovascular agents, process for producing the same and pharmaceutical compositions containing them
WO1999053091A3 (en) Dna coding for gdnf, parts of said dna and gdnf variants
HK1049485A1 (en) DithiepinoÄ6,5-BÜpyridines, and related compositions, methods of producing and uses.
HUP9904564A3 (en) Substituted aminomethyl-cycloheptenes, process for producing them, their use, and pharmaceutical compositions containing them
MXPA03004431A (en) Novel pharmaceutical compositions having an antidiabetic action, and process for their preparation.
WO2003040328A3 (en) Antisense modulation of thyroid hormone receptor interactor 6 expression
ZA991768B (en) Fragrance enhancing compositions for cosmetic products.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1997925049

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997925049

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997925049

Country of ref document: EP